USANA Health Sciences, Inc. (NYSE:USNA) major shareholder Global Ltd Gull sold 101,929 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $66.05, for a total value of $6,732,410.45. Following the sale, the insider now directly owns 11,996,192 shares in the company, valued at $792,348,481.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Global Ltd Gull also recently made the following trade(s):

  • On Monday, November 13th, Global Ltd Gull sold 7,289 shares of USANA Health Sciences stock. The shares were sold at an average price of $66.01, for a total value of $481,146.89.
  • On Thursday, November 2nd, Global Ltd Gull sold 43,292 shares of USANA Health Sciences stock. The shares were sold at an average price of $65.25, for a total value of $2,824,803.00.
  • On Thursday, October 26th, Global Ltd Gull sold 60,871 shares of USANA Health Sciences stock. The shares were sold at an average price of $67.39, for a total value of $4,102,096.69.
  • On Monday, October 30th, Global Ltd Gull sold 93,443 shares of USANA Health Sciences stock. The shares were sold at an average price of $67.08, for a total value of $6,268,156.44.
  • On Thursday, September 14th, Global Ltd Gull sold 79,294 shares of USANA Health Sciences stock. The shares were sold at an average price of $57.61, for a total value of $4,568,127.34.
  • On Tuesday, September 5th, Global Ltd Gull sold 40,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $58.41, for a total value of $2,336,400.00.

USANA Health Sciences, Inc. (NYSE USNA) traded up $0.15 on Thursday, reaching $66.00. The company had a trading volume of 136,493 shares, compared to its average volume of 128,351. The stock has a market capitalization of $1,582.31, a price-to-earnings ratio of 17.45 and a beta of 1.07. USANA Health Sciences, Inc. has a 12 month low of $52.55 and a 12 month high of $71.00.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.11. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.38%. The firm had revenue of $261.77 million during the quarter, compared to the consensus estimate of $259.52 million. During the same quarter in the previous year, the firm posted $2.40 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. equities research analysts expect that USANA Health Sciences, Inc. will post 3.7 EPS for the current year.

USANA Health Sciences announced that its board has authorized a stock buyback plan on Tuesday, July 25th that authorizes the company to buyback $64.60 million in shares. This buyback authorization authorizes the company to buy up to 46% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/16/usana-health-sciences-inc-usna-major-shareholder-sells-6732410-45-in-stock.html.

A number of research analysts have recently weighed in on the company. BidaskClub lowered USANA Health Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 22nd. Pivotal Research cut their price objective on USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday, July 26th.

Several institutional investors have recently bought and sold shares of USNA. BNP Paribas Arbitrage SA raised its stake in shares of USANA Health Sciences by 13.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock valued at $135,000 after acquiring an additional 245 shares in the last quarter. Victory Capital Management Inc. raised its stake in USANA Health Sciences by 17.6% in the second quarter. Victory Capital Management Inc. now owns 2,490 shares of the company’s stock worth $160,000 after buying an additional 373 shares in the last quarter. Creative Planning raised its stake in USANA Health Sciences by 528.0% in the second quarter. Creative Planning now owns 2,512 shares of the company’s stock worth $161,000 after buying an additional 2,112 shares in the last quarter. SG Americas Securities LLC bought a new position in USANA Health Sciences in the second quarter worth approximately $162,000. Finally, Cubist Systematic Strategies LLC bought a new position in USANA Health Sciences in the third quarter worth approximately $189,000. 44.54% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.